4.2 Review

The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney

期刊

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.mnh.0000437611.42417.7a

关键词

diabetic nephropathy; kidney; osteoprotegerin; TRAIL

资金

  1. Abbott Diabetes Care
  2. Novartis
  3. Roche Diagnostics
  4. Johnson & Johnson Medical
  5. Eli Lilly Italy
  6. Astra Zeneca
  7. Bristol Myers Squibb
  8. Merck Sharp Dohme
  9. Chiesi Farmaceutici
  10. Sigma-Tau
  11. ForFarma
  12. Novo Nordisk
  13. Rottapharm

向作者/读者索取更多资源

Purpose of reviewTumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a cytokine belonging to the TNF superfamily. TRAIL may modulate cell survival and proliferation through interaction with two different receptors, TRAIL-R1 and TRAIL-R2. The actions of TRAIL are regulated by three decoy receptors, TRAIL-R3, TRAIL-R4 and osteoprotegerin (OPG). There is evidence that both TRAIL and OPG are expressed by renal cells. The OPG/TRAIL axis has been recently linked to the pathogenesis of renal damage and, in particular, diabetic nephropathy.Recent findingsIn patients with kidney diseases, serum TRAIL and OPG levels are increased in parallel and are significantly associated with each other. In diabetic nephropathy, the renal expression of TRAIL and OPG is elevated, and in tubular cells proinflammatory cytokines enhance TRAIL expression. Additionally, a high-glucose microenvironment sensitizes tubular cells to apoptosis induced by TRAIL, whereas OPG counteracts the actions of TRAIL in cultured cells.SummaryIt seems that the expression and levels of TRAIL and OPG at serum and kidney levels are crucial for the pathogenesis of kidney diseases, and in particular diabetic nephropathy. Although further studies are necessary to clarify the exact role of the OPG/TRAIL axis in the kidney, this system seems to hold promise to provide therapeutic approaches for the management of renal damage.Video abstract availableSee the Video Supplementary Digital Content 1 (http://links.lww.com/CONH/A5).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据